Acute Cardiotoxicity With Concurrent Trastuzumab and Hypofractionated Radiation Therapy in Breast Cancer Patients

Mutlay Sayan¹, Zeinab Abou Yehia¹, Apar Gupta¹, Deborah Toppmeyer², Nisha Ohri¹ and Bruce G. Haffty¹*

¹ Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, United States, ² Department of Medicine, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, United States

Purpose: Radiotherapy for patients with non-metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer is commonly administered concurrently with adjuvant trastuzumab. However, there is limited data on the use of concurrent trastuzumab and hypofractionated radiotherapy (Hypo-RT), which is now standard of care for the majority of women receiving whole breast irradiation. In this study, we compared acute cardiotoxicity rates in HER2-positive breast cancer patients treated with concurrent trastuzumab and Hypo-RT or conventionally fractionated radiotherapy (Conv-RT).

Methods: We performed a review of our institutional database to identify HER2-positive breast cancer patients treated with trastuzumab and Hypo-RT or Conv-RT from 2005 to 2018 who underwent serial cardiac Left Ventricular Ejection Fraction (LVEF) evaluation. Decrease in LVEF was assessed by either echocardiography (ECHO) or multiple gated acquisition (MUGA) scan performed at baseline and every 3 months during trastuzumab therapy. Significant LVEF decline was defined as an absolute decrease in LVEF of ≥10% below the lower limit of normal or ≥16% from baseline value.

Results: We identified 41 patients treated with Hypo-RT and 100 patients treated with Conv-RT. Median follow-up was 32 months (range, 13–90 months). Baseline median LVEF was 62% (range, 50–81%) in Hypo-RT group and 64% (range, 51–76%) in Conv-RT group (p = 0.893). Final median LVEF was 60% (range, 50–75%) in both groups. Three patients (7%) in Hypo-RT and five (5%) in Conv-RT group developed significant asymptomatic LVEF decline (p = 0.203). There was no significant difference in mean heart dose in patients who developed significant asymptomatic LVEF decline vs. those who did not in Hypo-RT (p = 0.427) and Conv-RT (p = 0.354) groups. No symptomatic congestive heart failure was reported in either group.

Conclusions: The rate of asymptomatic LVEF decline in patients receiving concurrent trastuzumab and Hypo-RT was low (7%) and was similar to the rate observed in patients receiving Conv-RT. Longer follow-up is warranted to assess late cardiotoxicity.

Keywords: breast cancer, radiation therapy, hypofractionated breast irradiation, trastuzumab, cardiac toxicity
INTRODUCTION

The human epidermal growth factor receptor 2 gene (HER2) is overexpressed and/or amplified in approximately 20% of primary breast carcinomas and was historically considered a marker of poor prognosis (1, 2). Trastuzumab is a humanized monoclonal antibody that targets the extracellular domain of the HER2 oncoprotein (3). Multiple large randomized trials demonstrated reduced recurrence rates and improved survival with the use of adjuvant trastuzumab in HER2 positive breast cancer (4–8). In 2006, trastuzumab was approved by the US Food and Drug Administration (FDA) for the adjuvant treatment of localized HER2 positive breast cancer and is now standard of care.

Trastuzumab is generally well-tolerated; however, cardiac dysfunction (congestive heart failure [CHF] or decrease in left ventricular ejection fraction [LVEF]) remains a concern. While the overall incidence of cardiac toxicity is variable, likely due to inconsistent definitions used in trials, asymptomatic LVEF decline is the most frequent form of cardiotoxicity. In most trials, significant asymptomatic LVEF decline was defined as an absolute decrease in LVEF of ≥10% below the lower limit of normal or ≥16% from baseline, with incidence rates ranging from 3.5 to 18.6% (5–7, 9). Current guidelines therefore recommend assessment of LVEF at baseline and every 3 months during the therapy (10).

Adjuvant radiation therapy (RT) is standard of care after breast-conserving surgery and in patients at high risk for local relapse who undergo mastectomy. The risk of radiation-related long-term cardiotoxicity has been shown to increase in a dose-dependent fashion (11), and as a result radiotherapy techniques have been modernized to limit cardiac exposure. Conventionally fractionated radiotherapy (Conv-RT), or delivery of 1.8–2.0 Gy daily per fraction over 5–7 weeks was previously considered standard of care for all breast cancer patients requiring adjuvant radiotherapy. More recently, updated guidelines have endorsed a hypofractionated approach (Hypo-RT) for whole breast irradiation with delivery of over 2.0 Gy daily per fraction over 3–4 weeks (12).

Despite the common concurrent use of trastuzumab and radiotherapy in breast cancer, there is limited data on the safety of concurrent adjuvant trastuzumab administration and breast radiotherapy, particularly with hypofractionated radiotherapy. Preclinical data suggests a radiosensitizing effect of trastuzumab on breast cancer cells, but whether it causes radiosensitization of normal cells is unknown (13, 14). The potential synergistic effect of concurrent trastuzumab and RT on the heart remains a major concern, and can influence the routine use of hypofractionated radiation in patients with breast cancer, particularly in patients with left sided breast cancer (15, 16). While limited series have assessed acute cardiotoxicity with trastuzumab and Conv-RT, it is unknown whether the use of Hypo-RT with trastuzumab results in the same risks (17). In this study, we evaluate and compare cardiotoxicity rates in a cohort of HER2-positive breast cancer patients treated with adjuvant trastuzumab and concurrent Hypo-RT or Conv-RT.

METHODS

Patient Population

Using an IRB-approved protocol, we conducted a retrospective review of our institutional database to identify patients with stage I–III breast cancer from 2005 to 2018. The criteria for inclusion included: (1) HER2-positive disease; (2) receipt of Hypo-RT or Conv-RT; (3) concurrent receipt of trastuzumab; and (4) LVEF assessment by either echocardiography (ECHO) or multiple gated acquisition (MUGA) scan at baseline and every 3 months from the start of trastuzumab therapy.

Baseline Characteristics

Baseline clinical characteristics were collected and included patient age, race, and cardiac risk factors such as BMI ≥30, age ≥55 years, history of hypertension, hyperlipidemia, diabetes, CAD, smoking, and family history. Disease-related characteristics including histology, hormone receptor status, pre-chemotherapy clinical stage, and pathologic stage were also recorded. Treatment related factors included type of breast surgery (breast conserving surgery vs. mastectomy with or without reconstruction), receipt of chemotherapy (neoadjuvant vs. adjuvant chemotherapy), hormonal therapy, and adjuvant radiation therapy (Hypo-RT vs. Conv-RT).

Treatment

Neoadjuvant and adjuvant systemic chemotherapy and/or adjuvant hormone therapy was administered as clinically indicated in accordance with standard practices during this time interval. Breast-conserving surgery or mastectomy with or without regional nodal irradiation was performed. Axillary evaluation included sentinel node biopsy (SLNB) and/or axillary lymph node dissection (ALND).

Adjuvant RT was delivered using 3-dimensional conformal radiotherapy (3D-CRT) to the breast/chest wall with or without regional nodal irradiation. Boost was delivered as per physician discretion. Computed tomography–based treatment planning with tangential fields was used for all patients. The heart was excluded from the primary beam using multi-leaf collimator blocking. The deep inspiratory breath hold (DIBH) technique was utilized to limit cardiac exposure when clinically indicated.

Concurrent trastuzumab was administered every 3 weeks for up to 12 months at a standard dose of 2–6 mg/kg. Treatment was held if the LVEF dropped below 50% or when a patient developed any symptoms of heart failure. After a repeat evaluation at 4 weeks, if the LVEF was not recovered or in the case of confirmed congestive heart failure, trastuzumab was discontinued.

Follow-Up and Evaluation of Toxicity

Patients were seen weekly while undergoing radiation therapy and again around 1 month after completion of radiotherapy. Subsequent radiation oncology follow ups were typically around 6 months, 1 year, and yearly thereafter. Patients typically followed up with the medical oncologists every 1–3 months while undergoing chemotherapy, every 3–6 months for the following 2 years, and every 6–12 months thereafter. Follow-up was calculated from the time of radiotherapy completion.
TABLE 1 | Baseline characteristics.

|                  | Hypo-RT | Conv-RT | p     |
|------------------|---------|---------|-------|
| No. patients     | 41      | 100     | 0.053 |
| Race (%)         |         |         |       |
| White            | 26 (63) | 74 (74) |       |
| Black or African American | 6 (15) | 17 (17) |       |
| Asian            | 9 (22)  | 9 (9)   |       |
| Age (y)          |         |         | 0.334 |
| Median (range)   | 54 (38–78) | 53 (29–83) | 0.316 |
| Breast laterality (%) |      |         |       |
| Left             | 21 (51) | 54 (54) |       |
| Right            | 20 (49) | 46 (46) |       |
| Histology (%)    |         |         | 0.786 |
| IDC              | 40 (98) | 95 (95) |       |
| ILC              | 1 (2)   | 5 (5)   |       |
| Stage (%)        |         |         | 0.968 |
| IA               | 21 (51) | 17 (17) |       |
| IIA              | 13 (32) | 26 (26) |       |
| IIB              | 4 (10)  | 27 (27) |       |
| IIIA             | 1 (2)   | 15 (15) |       |
| IIIB             | 2 (5)   | 10 (10) |       |
| IIC              | 0       | 5 (5)   |       |
| Estrogen receptor (%) |     |         | 0.412 |
| Positive         | 20 (49) | 58 (58) |       |
| Negative         | 21 (51) | 42 (42) |       |
| Progesterone receptor (%) |   |         | 0.679 |
| Positive         | 19 (48) | 48 (48) |       |
| Negative         | 21 (51) | 50 (50) |       |
| Unknown          | 1 (2)   | 2 (2)   |       |
| Cardiac risk factors |       |         | <0.001|
| BMI ≥ 30         | 20 (49) | 41 (41) |       |
| Age ≥ 55 years   | 19 (48) | 38 (38) |       |
| Hypertension     | 19 (48) | 33 (33) |       |
| Hyperlipidemia   | 10 (24) | 18 (18) |       |
| Diabetes         | 7 (17)  | 14 (14) |       |
| CAD              | 1 (2)   | 4 (4)   |       |
| Smoking          | 14 (34) | 23 (23) |       |
| Family history   | 4 (10)  | 2 (2)   |       |
| Follow-up (months)|       |         | 0.243 |
| Mean             | 36      | 32      |       |
| Range            | 13.5–90 | 13–89.5 |       |

Hypo-RT, hypofractionated breast radiotherapy; Conv-RT, conventionally fractionated radiotherapy; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; BMI, body mass index; CAD, coronary artery disease.

Toxicities were scored using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) scale. Cardiac toxicity was evaluated by clinical assessment of cardiac function and by LVEF on ECHO or MUGA scans at baseline before starting trastuzumab, every 3 months during trastuzumab treatment, and at 3 months post-treatment if needed. Significant asymptomatic LVEF decline was defined as an absolute decrease in LVEF of ≥10% to below the lower limit of normal or ≥16% from baseline value.

Statistical Analysis

Statistical analyses were performed using SPSS statistical software version 25 (IBM Corp., Armonk, NY, USA). Categorical variables were compared using the Chi-squared and Fisher’s exact tests. Analysis of variance (ANOVA) was used for continuous variables. Cardiac risk factors were evaluated by univariate logistic regression.

RESULTS

We identified 141 patients who met the study criteria. Forty-one patients were treated with Hypo-RT and 100 patients with Conv-RT. Baseline patient characteristics are shown in Table 1. Median follow-up was 36 months (range, 13.5–90 months) in Hypo-RT group and 32 months (range, 13–89.5 months) in Conv-RT group (p = 0.243). The median age was 54 years (range, 38–78 years) in Hypo-RT group and 53 years (range, 29–83) in the Conv-RT group (p = 0.334). Laterality of the disease was similarly distributed in both treatment groups, with 51% of patients in the Hypo-RT group and 54% of patients in the Conv-RT group having left-sided disease (p = 0.316). The most common cardiac risk factors in both the Hypo-RT group and the Conv-RT group were BMI ≥30 (49 and 41%, respectively), age ≥55 years (46 and 38%, respectively), hypertension (46 and 33%, respectively), and smoking (34 and 23%, respectively). Patients in the Hypo-RT group had a significantly higher rate of cardiac risk factors (p < 0.001).

Treatment details are summarized in Table 2. Sixteen (39%) patients in Hypo-RT and 57 (57%) in Conv-RT group received neoadjuvant chemotherapy. The majority of patients (86% in Hypo-RT and 63% in Conv-RT) underwent breast-conserving surgery. Of the patients who received chemotherapy, a taxane-based regimen was the most common in both treatment groups. All patients received 12 months of trastuzumab. In Hypo-RT group, about 60% of patients received a dose of 42.56 Gy in 16 daily fractions. About 40% received a 3-week hypofractionated regimen of 36.63 Gy in 11 fractions followed by a 13.32 Gy boost in 4 fractions to the lumpectomy cavity on an institutional protocol. In the Conv-RT group, all patients received 5,000 cGy in 25 fractions. Over 90% of patients in both groups received a lumpectomy boost. Regional nodal irradiation was more common in the Conv-RT group (75% vs. 11%, p < 0.001). Mean heart dose was 101 cGy in Hypo-RT group and 163 cGy in Conv-RT group (p = 0.897).

Asymptomatic Changes in LVEF

Baseline median LVEF was 62% (range, 50–81%) in Hypo-RT group and 64% (range, 51–76%) in Conv-RT group (p = 0.893), and final median LVEF was 60% in both treatment groups (p = 0.998) (Table 3, Figure 1). As shown in Table 3, over 80% of patients from both groups had no decrease in LVEF from baseline or a <10% decrease in LVEF. The rate of significant asymptomatic LVEF decline (≥16% from baseline) was not significantly different between the treatment groups (7 vs. 5%, p = 0.203). No patients developed symptomatic CHF in either group.
Among the three patients (7%) treated with Hypo-RT who developed significant asymptomatic LVEF decline, only one had left-sided breast cancer. All three patients received a taxane-based chemotherapy regimen. Baseline LVEF was higher in all three patients compared to the median value (81, 72, and 68%). Two patients had diabetes and BMI $\geq 30$, and one had hyperlipidemia. On univariate analysis, history of smoking ($p = 0.307$), CAD ($p = 0.925$), hypertension ($p = 0.519$), diabetes ($p = 0.07$), hyperlipidemia ($p = 0.619$), and BMI $\geq 30$ ($p = 0.519$) had no significant effect on the development of significant asymptomatic LVEF decline. There was no significant difference in mean heart dose in patients who developed significant asymptomatic LVEF decline compared to those who did not ($p = 0.427$). Similar findings were noted for the five (5%) patients treated with Conv-RT who developed significant asymptomatic LVEF decline.

**Toxicity**

Table 4 lists additional non-cardiac radiation treatment-related toxicities. Grade 2 skin toxicity was the most frequent toxicity reported in both groups (12% in Hypo-RT and 27% in Conv-RT group). All toxicities were acute and resolved during follow-up, with the exception of one patient with grade 2 lymphedema in the Hypo-RT group and two in the Conv-RT group. There were no grade 3 or 4 toxicities.

**DISCUSSION**

Within a cohort of HER2-positive breast cancer patients treated with concurrent trastuzumab and Hypo-RT or Conv-RT, we note three main findings: (1) No symptomatic cardiac toxicity occurred; (2) Rates of significant asymptomatic LVEF decline in both groups were similarly low and within the range reported by randomized trials with trastuzumab; and (3) Development of asymptomatic LVEF decline was independent of multiple dosimetric cardiac parameters including mean heart dose.

Breast cancer patients have a higher rate of cardiac disease compared to age matched controls without cancer (18, 19). This increased rate of cardiac disease is due to shared risk factors for cardiac disease and breast cancer and also cancer therapy related cardiotoxicities (20–23). Traditionally, RT-associated cardiotoxicity was thought to manifest $> 10$ years after treatment (24–26). However, Darby et al. reported that the greatest percentage increase in the rate of major coronary artery events per Gy of heart irradiation occurred within the first 4 years after RT for breast cancer patients (11). Additionally, Marks et al. found that 6 and 12 months after RT for breast cancer, 27 and 29% of patients, respectively, had evidence of new cardiac perfusion defects (27). Furthermore, the interaction between RT-associated cardiotoxicity and trastuzumab-related cardiotoxicity is not well studied with modern adjuvant radiotherapy regimens.
As hypofractionated radiotherapy is now the standard of care for the majority of women receiving whole breast irradiation, it is important to assess the safety of combining Hypo-RT with concurrent trastuzumab.

Major international trials reported the role of trastuzumab in improving survival and quality of life in HER2-positive breast cancer patients. These trials also demonstrated that cardiac events were increased with adjuvant trastuzumab (Table 5). However, the timing of trastuzumab administration was different in these trials. In the Herceptin Adjuvant (HERA) trial, trastuzumab was started after both chemotherapy and RT (5), and in the Finnish Herceptin (FinHer) trial, RT was started after trastuzumab (28). In the NSABP-B31, NCCTG-9831, and Breast Cancer International Research Group 006 (BCIRG-006) trials, RT was administered with trastuzumab (6, 7).

Asymptomatic LVEF decline is the most frequent form of cardiotoxicity associated with trastuzumab, with incidence rates in randomized trials ranging from 3.5 to 18.6% (Table 5). Specifically in the three large randomized trials with concurrent RT and trastuzumab, the incidence of asymptomatic LVEF decline ranged from 10.8 to 18.6%. In our study, 7% of the patients treated with Hypo-RT and 5% treated with Conv-RT experienced significant asymptomatic LVEF decline. Bonzano et al. recently compared the decrease in LVEF in HER2-positive patients treated with trastuzumab and various Hypo-RT schemes (46 Gy/20 fractions, 39 Gy/13 fractions, and 35 Gy/10 fractions) (17). Cardiotoxicities were assessed according to Common Terminology Criteria for Adverse Events v3 (CTCAE) and no difference in LVEF decline in these Hypo-RT schemes were reported. Since the assessment of LVEF decline in randomized trials is different, it is not possible to compare the result of this study with others.

During or shortly after radiotherapy, the majority of the patients experience some degree of acute RT-induced skin toxicity. The acute skin reaction is expected to be low with Hypo-RT compared to Conv-RT. During Hypo-RT, 24–27% patients experience ≥ grade 2 skin toxicity (29, 30). Rates of RT-induced acute skin toxicity further decrease in those also treated with trastuzumab. Meattini et al. retrospectively reviewed 95 patients treated with Conv-RT with trastuzumab (31). Grade 2 or more acute skin toxicity was reported in 14% of the patients. In the NCCTG-9831 trial, 5.3% of the patient experienced ≥ grade 3 skin toxicity (32). In our study, no grade 3 toxicity was reported and only 12% of the patients treated with Hypo-RT experienced grade 2 skin toxicity demonstrating no adverse skin toxicity associated with hypofractionated radiation.

A strength of our study is the detailed serial cardiac evaluation that was documented in the entire cohort. Although retrospective, the nearly identical baseline and serial cardiac function observed between the Hypo-RT and Conv-RT groups should be reassuring regarding the safety of administering concurrent trastuzumab and Hypo-RT in patients with breast cancer.
cancer, irrespective of laterality. These data can help reduce the use of adjuvant trastuzumab as a potential barrier to the adoption of hypofractionated radiation in patients with left sided breast cancer (12, 33). In all patients undergoing radiation, however, careful detailed simulation with deep inspiration breath hold or other techniques should be employed to limit dose to the heart to as low as is reasonably achievable. Given the low mean heart dose in our cohort, caution must be taken when extrapolating these results to facilities where such techniques are not available to decrease mean heart dose.

A limitation to our study is of course its retrospective design and inherent confounding factors that cannot be totally accounted for in a non-randomized study. In addition, the small sample size and limited follow-up do not adequately address potential long-term cardiotoxicity. However, the detailed serial cardiac function evaluations were consistent with the plethora of available literature on cardiac function changes in patients undergoing chemotherapy for breast cancer and there was no evidence that hypofractionation or conventional fractionation significantly compromised or impacted LVEF.

In conclusion, the rate of asymptomatic LVEF decline in patients receiving concurrent trastuzumab and Hypo-RT was similar to those treated with Conv-RT and was independent of mean heart dose. Longer follow-up is warranted to assess late cardiotoxicity.

DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING

This work was supported in part by the Breast Cancer Research Foundation.

REFERENCES

1. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. (2004) 5:63–9. doi: 10.3816/CBC.2004.n.011
2. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist. (1998) 3:237–52. doi: 10.1002/scc.160413
3. Huds CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med. (2007) 357:39–51. doi: 10.1056/NEJMra043186
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. (2001) 344:783–92. doi: 10.1056/NEJMoa013154
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. (2005) 353:1659–72. doi: 10.1056/NEJMoa052306
6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. (2005) 353:1673–84. doi: 10.1056/NEJMoa052122
7. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. (2011) 365:1273–83. doi: 10.1056/NEJMoa0910383
8. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. (2014) 32:3744–52. doi: 10.1200/JCO.2014.55.3730
9. Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. (2005) 23:7811–9. doi: 10.1200/JCO.2005.0 24091
10. Armen SH, Lachetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. (2017) 35:893–911. doi: 10.1200/JCO.2016.7 05400
23. Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA. Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol. (2014) 32:927–34. doi: 10.1200/JCO.2013.51.1261

24. Cuzick J, Stewart H, Rutqvist L, Houghton J, Edwards R, Redmond C, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. (1994) 12:447–53. doi: 10.1200/JCO.1994.12.3.447

25. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. (2005) 6:537–65. doi: 10.1016/S1470-2045(05)70251-5

26. Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. (2007) 99:365–75. doi: 10.1093/jnci/djk064

27. Marks LB, Yu X, Prosnitz RG, Zhou SM, Hardenbergh PH, Blazing M, et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. (2005) 63:214–23. doi: 10.1016/j.ijrobp.2005.01.029

28. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. (2009) 27:5685–92. doi: 10.1200/JCO.2008.21.4577

29. Khan AJ, Poppe MM, Goyal S, Kokeny KE, Kearney T, Kirstein L, et al. Hypofractionated postmastectomy radiation therapy is safe and effective: first results from a prospective phase II trial. J Clin Oncol. (2017) 35:2037–43. doi: 10.1200/JCO.2016.70.7158

30. Jagoi R, Griffith KA, Boike TP, Walker E, Nurushev T, Grills IS, et al. Differences in the acute toxic effects of breast radiotherapy by fractionation schedule: comparative analysis of physician-assessed and patient-reported outcomes in a large multicenter cohort. JAMA Oncol. (2015) 1:918–30. doi: 10.1001/jamaoncol.2015.2590

31. Meattini L, Cecchini S, Muntoni C, Scotti V, De Luca Cardillo C, Mangoni M, et al. Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series. Med Oncol. (2014) 31:891. doi: 10.1007/s12032-014-0891-x

32. Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III trial N9831. J Clin Oncol. (2009) 27:2638–44. doi: 10.1200/JCO.2008.17.9549

33. Bekelman JE, Malin J, Emanuel EJ. Hypofractionated whole breast irradiation for early-stage breast cancer—reply. JAMA. (2015) 313:1371. doi: 10.1001/jama.2015.1644

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Sayan, Abou Yehia, Gupta, Toppmeyer, Ohri and Haffty. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.